Related Experiment Video
Updated: Feb 28, 2026
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease
Karina Thieme1, Syamantak Majumder1, Angela S Brijmohan1
1Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
Abstract:
The therapeutic targeting of prostanoid subtype receptors may slow the development of chronic kidney disease (CKD) through mechanisms that are distinct from those of upstream COX inhibition. Here, employing multiple experimental models of CKD, we studied the effects of inhibition of the EP4 receptor, one of four receptor subtypes for the prostanoid prostaglandin E2. In streptozotocin-diabetic endothelial nitric oxide synthase knockout mice, EP4 inhibition attenuated the development of albuminuria, whereas the COX inhibitor indomethacin did not. In Type 2 diabetic db/db mice, EP4 inhibition lowered albuminuria to a level comparable with that of the ACE inhibitor captopril. However, unlike captopril, EP4 inhibition had no effect on blood pressure or hyperfiltration although it did attenuate mesangial matrix accumulation. Indicating a glucose-independent mechanism of action, EP4 inhibition also attenuated proteinuria development and glomerular scarring in non-diabetic rats subjected to surgical renal mass ablation. Finally, in vitro, EP4 inhibition prevented transforming growth factor-ß1 induced dedifferentiation of glomerular podocytes. In rodent models of diabetic and non-diabetic CKD, EP4 inhibition attenuated renal injury through mechanisms that were distinct from either broadspectrum COX inhibition or "standard of care" renin angiotensin system blockade. EP4 inhibition may represent a viable repurposing opportunity for the treatment of CKD.
Insights
Targeting the EP4 receptor may slow chronic kidney disease (CKD) progression. EP4 inhibition reduced kidney injury in diabetic and non-diabetic models, offering a new therapeutic strategy distinct from current treatments.
Area of Science:
- Nephrology
- Pharmacology
- Molecular Biology
Background:
- Chronic kidney disease (CKD) is a progressive condition with limited treatment options.
- Current therapies like COX inhibitors and renin-angiotensin system blockers have limitations.
- Prostanoid signaling, particularly prostaglandin E2 (PGE2) acting via its EP4 receptor, is implicated in kidney injury.
Purpose of the Study:
- To investigate the therapeutic potential of EP4 receptor inhibition in experimental models of CKD.
- To compare the efficacy of EP4 inhibition with established treatments like COX inhibitors and ACE inhibitors.
- To elucidate the mechanisms by which EP4 inhibition may attenuate renal injury.
Main Methods:
- Utilized multiple rodent models of CKD, including streptozotocin-induced diabetes, Type 2 diabetic db/db mice, and surgically induced renal mass ablation.
- Administered EP4 receptor inhibitors, indomethacin (COX inhibitor), and captopril (ACE inhibitor).
- Assessed outcomes including albuminuria, blood pressure, hyperfiltration, mesangial matrix accumulation, proteinuria, glomerular scarring, and podocyte dedifferentiation in vitro.
Main Results:
- EP4 inhibition attenuated albuminuria in diabetic mice, an effect not seen with indomethacin.
- EP4 inhibition reduced albuminuria comparably to captopril in db/db mice, without affecting blood pressure or hyperfiltration, but reduced mesangial matrix.
- EP4 inhibition mitigated proteinuria and glomerular scarring in non-diabetic rats and prevented TGF-ß1-induced podocyte dedifferentiation in vitro.
Conclusions:
- EP4 receptor inhibition demonstrates renoprotective effects in diverse CKD models.
- These benefits are achieved through mechanisms independent of COX inhibition and renin-angiotensin system blockade.
- EP4 inhibition represents a promising therapeutic strategy for CKD, potentially through podocyte protection and matrix regulation.
More Related Videos
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:23Dipeptidyl Peptidase 4 Inhibitors
01:28Chronic Kidney Disease III: Interprofessional Care